Should the short‑acting (rapid‑acting) insulin dose be increased for an adult patient with a blood glucose of 546 mg/dL?

Yes, increase the short-acting insulin dose for a blood glucose of 546 mg/dL

For a blood glucose of 546 mg/dL, you should administer supplemental rapid-acting insulin according to a correction scale, typically 14-18 units depending on insulin sensitivity, and investigate for ketosis in insulin-treated patients. 1

Immediate Management Algorithm

Step 1: Assess Clinical Context

• Check for ketosis immediately if the patient has type 1 diabetes or type 2 diabetes on insulin therapy 2
• Measure ketonuria or ketonaemia to rule out diabetic ketoacidosis
• Assess for signs of hyperosmolar hyperglycemic state in type 2 diabetes patients (altered mental status, severe dehydration)

Step 2: Administer Correction Insulin

For a glucose of 546 mg/dL (≥400 mg/dL category), use the following correction doses based on insulin sensitivity 1:

• Insulin-sensitive patients: 14 units rapid-acting insulin
• Usual sensitivity: 16 units rapid-acting insulin
• Insulin-resistant patients: 18 units rapid-acting insulin

Start with the "usual" column (16 units) unless:

• Patient is elderly, has impaired renal function, or is not eating → use insulin-sensitive column (14 units)
• Patient is on corticosteroids or was taking >80 units/day at home → use insulin-resistant column (18 units)

Step 3: Ensure Adequate Hydration

Initiate good hydration alongside insulin administration 2

Step 4: Determine If Scheduled Insulin Is Needed

If this patient is only on correction insulin and has had ≥2 blood glucose measurements ≥180 mg/dL in 24 hours, you must add scheduled basal-bolus insulin therapy 3. A glucose of 546 mg/dL indicates severe hyperglycemia requiring:

• Total daily dose: 0.5 units/kg/day for glucose 201-400 mg/dL range 1
• Distribute as 50% basal insulin and 50% nutritional (prandial) insulin
• Give basal insulin once daily (glargine/detemir)
• Give rapid-acting insulin in three divided doses before meals

Step 5: Monitor Response

• Recheck blood glucose in 3-4 hours after rapid-acting insulin administration
• If ketosis was present, recheck ketones at 3 hours 2

Critical Pitfalls to Avoid

Do not rely solely on sliding-scale insulin for persistent hyperglycemia. The 2012 Endocrine Society guideline explicitly warns that sliding-scale insulin as monotherapy increases the risk of hyperglycemia 3-fold 1. At a glucose of 546 mg/dL, this patient needs scheduled insulin therapy, not just correction doses.

Do not delay insulin administration while waiting for ketone results in a stable patient without signs of DKA. Give the correction dose immediately and check ketones simultaneously 2.

Watch for insulin resistance indicators: If this patient requires >5 units/hour on IV insulin or correction doses consistently in the insulin-resistant range, consider underlying causes (infection, corticosteroids, critical illness) 2.

Special Considerations

For type 1 diabetes or DKA: If ketosis is present (ketonaemia ≥1.5 mmol/L or ketonuria 2+), transfer to ICU for IV insulin infusion 2. Do not manage severe DKA with subcutaneous insulin alone.

For type 2 diabetes: Rule out hyperosmolar hyperglycemic state if glucose >300 mg/dL with altered mental status or severe dehydration. This requires ICU-level care 2.

The most recent 2022 Endocrine Society guideline 3 reinforces that persistent hyperglycemia (≥180 mg/dL) requires scheduled insulin, and a glucose of 546 mg/dL far exceeds this threshold, mandating both immediate correction and initiation of a basal-bolus regimen if not already in place.